TriSalus Life Sciences Files 8-K

TL;DR

TriSalus Life Sciences filed a routine 8-K on July 1st. No major news.

AI Summary

TriSalus Life Sciences, Inc. filed an 8-K on July 1, 2024, reporting other events and financial statements. The company, formerly known as MedTech Acquisition Corp, is incorporated in Delaware and headquartered in Westminster, Colorado. The filing does not disclose specific financial transactions or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates TriSalus Life Sciences is fulfilling its regulatory reporting obligations, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting purposes and does not contain information indicating significant new risks.

Key Players & Entities

• TriSalus Life Sciences, Inc. (company) — Registrant
• MedTech Acquisition Corp (company) — Former company name
• July 1, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Westminster, Colorado (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share TLSI Nasdaq Glo
• $11.50 — of Common Stock at an exercise price of $11.50 per share TLSIW Nasdaq Global Marke

Filing Documents

• tm2418573d1_8k.htm (8-K) — 30KB
• tm2418573d1_ex99-1.htm (EX-99.1) — 12KB
• 0001104659-24-076841.txt ( ) — 263KB
• tlsi-20240701.xsd (EX-101.SCH) — 3KB
• tlsi-20240701_def.xml (EX-101.DEF) — 26KB
• tlsi-20240701_lab.xml (EX-101.LAB) — 36KB
• tlsi-20240701_pre.xml (EX-101.PRE) — 25KB
• tm2418573d1_8k_htm.xml (XML) — 5KB

01

Item 8.01 Other Events. On July 1, 2024, TriSalus Life Sciences, Inc., a Delaware corporation (the "Company"), issued a press release announcing the closing of (i) its previously announced offer (the "Offer") to all holders of each class of certain outstanding warrants (the "Warrants"), consisting of (a) the Company's publicly-traded Warrants listed on the Nasdaq Global Market under the symbol "TLSIW", (b) certain Warrants issued in a private placement transaction occurring simultaneously with the closing of the initial public offering of the Company and (c) certain Warrants issued for working capital requirements and payment of certain expenses of the Company, each identified in the Prospectus/Offer to Exchange that forms a part of the Company's Registration Statement on Form S-4 (Registration No. 333- 279691), filed with the U.S. Securities and Exchange Commission on May 24, 2024, to receive 0.3 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), in exchange for each Warrant tendered by the holder and exchanged pursuant to the Offer, and (ii) the solicitation of consents (the "Consent Solicitation") from holders of the Warrants to amend the Warrant Agreement, dated as of December 17, 2020, by and between the Company and Continental Stock Transfer & Trust Company, which governs all of the Warrants. At the closing of the Offer and Consent Solicitation, the Company issued 2,110,366 shares of Common Stock in exchange for the Warrants tendered in the Offer. A copy of the press release is attached as Exhibit 99.1 and is incorporated by reference herein.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibit Number Description 99.1 Press Release, dated July 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRISALUS LIFE SCIENCES, INC. By: /s/ Sean Murphy Sean Murphy Chief Financial Officer Dated: July 1, 2024

View Full Filing

View this 8-K filing on SEC EDGAR